Related Experiment Video

Updated: Aug 6, 2026

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Beta-secretase (BACE) and GSK-3 mRNA levels in Alzheimer's disease

Paul Preece1, David J Virley, Moheb Costandi

  • 1Quantuum, Departamento de Neurología, Rua das Brañas 7-bajo-D, Mera, La Coruña, Galicia 15177, Spain. pablo@quantuum.com

Brain Research. Molecular Brain Research
|August 28, 2003
PubMed

Insights

This study investigated beta-secretase (BACE) and glycogen synthase kinase (GSK 3) in Alzheimer's disease brains. Researchers found no significant difference in mRNA levels for these enzymes between Alzheimer's patients and control subjects.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
  • Beta-secretase (BACE) and glycogen synthase kinase 3 (GSK 3) are implicated in AD pathogenesis.
  • Understanding the molecular mechanisms of AD is crucial for developing effective treatments.

Purpose of the Study:

  • To quantify mRNA levels of BACE and GSK 3alpha in Alzheimer's disease brains.
  • To compare enzyme mRNA levels between Alzheimer's patients and healthy controls.
  • To investigate the potential role of BACE and GSK 3alpha in AD.

Main Methods:

  • Extraction of mRNA from post-mortem brain tissue (90 Alzheimer, 81 control).
  • Quantification of BACE and GSK 3alpha mRNA using TaqMan real-time RT-PCR.
  • Statistical comparison of mRNA levels between disease and control groups.

Main Results:

  • No significant difference was observed in BACE mRNA levels between Alzheimer's and control brains.
  • No significant difference was observed in GSK 3alpha mRNA levels between Alzheimer's and control brains.
  • These findings suggest BACE and GSK 3alpha mRNA levels may not be altered in AD.

Conclusions:

  • The study did not find altered mRNA expression of BACE or GSK 3alpha in Alzheimer's disease brains.
  • Further research is needed to fully elucidate the role of these enzymes in Alzheimer's disease.
  • Investigating protein levels and activity may provide additional insights.

More Related Videos

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase11:57

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...